[go: up one dir, main page]

NO20000752L - Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser - Google Patents

Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser

Info

Publication number
NO20000752L
NO20000752L NO20000752A NO20000752A NO20000752L NO 20000752 L NO20000752 L NO 20000752L NO 20000752 A NO20000752 A NO 20000752A NO 20000752 A NO20000752 A NO 20000752A NO 20000752 L NO20000752 L NO 20000752L
Authority
NO
Norway
Prior art keywords
disorders
preventing
dependent diseases
treating estrogen
estrogen
Prior art date
Application number
NO20000752A
Other languages
English (en)
Other versions
NO20000752D0 (no
Inventor
Donald P Mcdonnell
John Norris
Caroline Connor
Ashini Wijayaratne
Original Assignee
Univ Duke
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Duke filed Critical Univ Duke
Publication of NO20000752D0 publication Critical patent/NO20000752D0/no
Publication of NO20000752L publication Critical patent/NO20000752L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20000752A 1997-08-15 2000-02-15 Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser NO20000752L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5588197P 1997-08-15 1997-08-15
PCT/US1998/016864 WO1999008682A1 (en) 1997-08-15 1998-08-14 A method of preventing or treating estrogen-dependent diseases and disorders

Publications (2)

Publication Number Publication Date
NO20000752D0 NO20000752D0 (no) 2000-02-15
NO20000752L true NO20000752L (no) 2000-02-15

Family

ID=22000784

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20000752A NO20000752L (no) 1997-08-15 2000-02-15 Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser

Country Status (21)

Country Link
US (1) US7307102B2 (no)
EP (1) EP1019057B1 (no)
JP (1) JP2001515038A (no)
KR (1) KR20010022956A (no)
CN (1) CN1275911A (no)
AT (1) ATE411016T1 (no)
AU (1) AU757206B2 (no)
BR (1) BR9811946A (no)
CA (1) CA2301032C (no)
CZ (1) CZ300929B6 (no)
DE (1) DE69840126D1 (no)
EE (1) EE200000077A (no)
ES (1) ES2312189T3 (no)
HU (1) HUP0002852A3 (no)
IL (1) IL134445A0 (no)
NO (1) NO20000752L (no)
NZ (1) NZ502738A (no)
PL (1) PL338555A1 (no)
RU (1) RU2214236C2 (no)
UA (1) UA70925C2 (no)
WO (1) WO1999008682A1 (no)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
AU4676999A (en) * 1998-06-12 1999-12-30 Ligand Pharmaceuticals, Inc. Treatment of anti-estrogen resistant breast cancer using rxr modulators
GB9824207D0 (en) * 1998-11-04 1998-12-30 Zeneca Ltd Neurological disorders
DK1196163T3 (da) * 1999-07-06 2010-03-29 Endorech Inc Farmaceutiske sammensætninger til behandling af insulinresistens
CO5271709A1 (es) 2000-01-12 2003-04-30 Pfizer Prod Inc Composiciones y procedimientos para el y tratamiento de afecciones que responden a estrogenos
US6417394B2 (en) * 2000-04-05 2002-07-09 Bristol Myers Squibb Pharma Company Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators
US6528681B2 (en) 2000-04-05 2003-03-04 Bristol-Meyers Squibb Pharma Company Halogenated triphenylethylene derivatives as selective estrogen receptor modulators
USRE41236E1 (en) * 2000-07-05 2010-04-20 Seely Andrew J E Method and apparatus for multiple patient parameter variability analysis and display
ES2318000T3 (es) * 2001-02-15 2009-05-01 Janssen Pharmaceutica Nv Combinaciones de inhibidores de la farnesil-protein-transferasa con agentes antiestrogenos.
US20020164581A1 (en) * 2001-03-12 2002-11-07 Chawnshang Chang Methods for identifying compounds that do not attenuate the protective effects of estrogen
HUP0500573A2 (hu) * 2001-08-11 2005-11-28 Bristol-Myers Squibb Pharma Company Trifenil-etilén származékok, mint szelektív ösztrogén receptor modulátorok és ezeket tartalmazó gyógyszerkészítmények
JP4855396B2 (ja) 2004-06-23 2012-01-18 リビジョン セラピューティクス， インコーポレイテッド レチナール誘導体で眼科的な状態を処置するための方法および組成物
US7432307B2 (en) 2004-11-04 2008-10-07 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (RBP)-transthyretin (TTR) complex formation
EA011154B1 (ru) * 2004-12-08 2009-02-27 Сирион Терапьютикс, Инк. Композиции для лечения ретинол-ассоциированных заболеваний
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
JP2010540127A (ja) 2007-10-03 2010-12-24 オタワ ヘルス リサーチ インスティチュート １つ以上の臓器の経時的生理的パラメータ変動を監視するための方法および装置
US8232402B2 (en) 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
SG185637A1 (en) 2010-06-10 2012-12-28 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
WO2011159769A2 (en) 2010-06-17 2011-12-22 Aragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
GB2483736B (en) 2010-09-16 2012-08-29 Aragon Pharmaceuticals Inc Estrogen receptor modulators and uses thereof
JP2015500346A (ja) 2011-12-14 2015-01-05 セラゴン ファーマシューティカルズ，インク． エストロゲン受容体モジュレーターおよびその使用
CN102584687A (zh) * 2011-12-30 2012-07-18 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
CN102532073A (zh) * 2011-12-30 2012-07-04 北京赛林泰医药技术有限公司 作为选择性雌激素受体调节剂的乙烯衍生物
KR20140138296A (ko) 2012-03-20 2014-12-03 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조절제 및 이의 용도
MX393926B (es) * 2015-12-09 2025-03-24 Univ Illinois Reguladores a la baja del receptor de estrógeno selectivo de benzotiofeno.
CN111094227A (zh) * 2017-07-28 2020-05-01 里科瑞尔姆Ip控股有限责任公司 丙烯酸类似物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE637389A (no) 1962-09-13
GB1029221A (en) 1963-09-02 1966-05-11 Ici Ltd Triarylalkane derivatives
GB1079747A (en) 1965-07-07 1967-08-16 Ici Ltd Alkene derivatives
US3637856A (en) 1965-07-12 1972-01-25 Ici Ltd Trans-1-p-(dialkylaminoalkyl) phenyl-1 2-diphenyl-alk-1-enes and salts thereof
GB1128379A (en) 1966-06-20 1968-09-25 Ici Ltd Novel alkene derivatives, process for the preparation thereof and compositions containing the same
GB1560274A (en) 1977-02-28 1980-02-06 Ici Ltd Phenylbut 1-ene derivatives having antiostrogenicactivity
EP0002097B1 (en) 1977-08-22 1981-08-05 Imperial Chemical Industries Plc Triphenylalkene derivatives, process for their preparation and pharmaceutical compositions containing them
US4206234A (en) 1977-08-22 1980-06-03 Imperial Chemical Industries Limited Triphenylbut-1-ene derivatives and pharmaceutical compositions and uses thereof
EP0019377B1 (en) 1979-05-15 1982-08-04 Imperial Chemical Industries Plc 1-hydrocarbyloxyphenyl-1,2-diphenylalkene derivatives, their manufacture and a pharmaceutical composition containing them
HU178253B (en) 1979-08-15 1982-04-28 Gyogyszerkutato Intezet Process for preparing 1,1,2-triphenyl-propane and -propane derivatives
DE3046719C2 (de) 1980-12-11 1983-02-17 Klinge Pharma GmbH, 8000 München 1,1,2-Triphenyl-but-1-en-Derivate, Verfahren zu ihrer Herstellung und Arzneimittel
FI77839C (fi) 1982-05-27 1989-05-10 Farmos Oy Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat.
US5491173A (en) * 1982-06-25 1996-02-13 Orion-Yhtyma Oy Tri-phenyl alkene derivatives and their preparation and use
CA1229604A (en) 1984-02-14 1987-11-24 Lorne J. Brandes Aminoalkyl ethers of phenols as antiproliferative anticancer agents
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
GB8604528D0 (en) 1986-02-24 1986-04-03 Ici Plc Therapeutic agents
US4859695A (en) 1986-06-10 1989-08-22 Merck & Co., Inc. Antiestrogen agents having anabolic activity in animals
CA1289570C (en) 1986-06-16 1991-09-24 Tetsuji Asao 1,1,2-triaryl-1-alkene derivatives
DE3736682A1 (de) 1987-10-29 1989-05-11 Klinge Co Chem Pharm Fab Verfahren zur herstellung von trans-1,1,2-triphenyl-but-1-en-derivaten
US5393785A (en) 1988-10-31 1995-02-28 Endorecherche, Inc. Therapeutic antiestrogens
US5119827A (en) 1990-09-05 1992-06-09 Board Of Regents, The University Of Texas System Mechanisms of antiestrogen resistance in breast cancer
US5189212A (en) 1990-09-07 1993-02-23 University Of Georgia Research Foundation, Inc. Triarylethylene carboxylic acids with estrogenic activity
WO1992006068A1 (en) 1990-10-01 1992-04-16 Board Of Regents, The University Of Texas System High affinity tamoxifen derivatives and uses thereof
EP0589039A1 (en) 1991-04-30 1994-03-30 Asahi Kasei Kogyo Kabushiki Kaisha Triphenylethylene derivative and pharmaceutical preparation containing the same
EP0660821B1 (en) 1992-09-15 1998-01-21 Merrell Pharmaceuticals Inc. Non-metabolizable clomiphene analogs for treatment of tamoxifen-resistant tumors
DE4311870C2 (de) * 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5455275A (en) * 1994-05-11 1995-10-03 Eli Lilly And Company Methods for inhibiting endometriosis and uterine fibroid disease with 1,1,2-triphenylbut-1-ene derivatives

Also Published As

Publication number Publication date
WO1999008682A1 (en) 1999-02-25
IL134445A0 (en) 2001-04-30
PL338555A1 (en) 2000-11-06
RU2214236C2 (ru) 2003-10-20
EP1019057B1 (en) 2008-10-15
CN1275911A (zh) 2000-12-06
CA2301032C (en) 2009-01-13
AU8906398A (en) 1999-03-08
HUP0002852A2 (hu) 2001-10-28
CZ300929B6 (cs) 2009-09-16
NO20000752D0 (no) 2000-02-15
ATE411016T1 (de) 2008-10-15
CA2301032A1 (en) 1999-02-25
AU757206B2 (en) 2003-02-06
HUP0002852A3 (en) 2001-11-28
US7307102B2 (en) 2007-12-11
JP2001515038A (ja) 2001-09-18
DE69840126D1 (de) 2008-11-27
US20030232795A1 (en) 2003-12-18
EE200000077A (et) 2000-12-15
EP1019057A1 (en) 2000-07-19
UA70925C2 (uk) 2004-11-15
ES2312189T3 (es) 2009-02-16
BR9811946A (pt) 2000-08-22
KR20010022956A (ko) 2001-03-26
EP1019057A4 (en) 2006-06-14
CZ2000531A3 (en) 2001-05-16
NZ502738A (en) 2002-06-28

Similar Documents

Publication Publication Date Title
NO20000752D0 (no) Metode for forhindring eller behandling av østrogen-avhengige sykdommer og forstyrrelser
ATE208382T1 (de) Konjugate von cis-docosahexaensäure und paclitaxel
ATE425749T1 (de) Behandlung von mit her-2/neu-uberexprimierung einhergehendem krebs
NO970039D0 (no) Fremgangsmåte for inhibering av cancer matastaser ved oral administrering av opplöselig modifisert sitruspektin
DE69826695D1 (de) Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
CY1109525T1 (el) ΑΝΘΡΩΠΟΠΟΙΗΜΕΝΑ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2 ΚΑΙ ΘΕΡΑΠΕΥΤΙΚΗ ΑΓΩΓΗ ΜΕ ΑΝΤΙΣΩΜΑΤΑ ΑΝΤΙ-ErbB2
HUP9801826A2 (hu) HER-2/neu-fehérje intracelluláris doménje, és alkalmazása malignitások megelőzésére és kezelésére
GB9815177D0 (en) Treatment of skin disorders
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE239509T1 (de) Konjugate zur behandlung von prostatakrebs
PT1109571E (pt) Metodos de tratamento da hipertensao e composicoes para utilizacao nesses metodos
DE69927688D1 (de) Antivirales Mittel in Kombination mit Strahlentherapie zur Verwendung in der Behandlung von Krebs
ATE196083T1 (de) Verwendung von ferrioxamin-b zur behandlung septischen schocks
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
MD1569G2 (ro) Metodă de tratament al cancerului mamar în perioada preoperatorie
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
MXPA01007031A (es) Metodo para tratar enfermedades acrdiacas cronicas.
DE60212415D1 (de) Die verwendung von einer 4-pyridylmethylphtalazine enthaltenden kombination zur behandlung von tumoren
UA34368A (uk) Спосіб лікування рака молочної залози
UA34375A (uk) Спосіб лікування рака молочної залози
UA36485A (uk) Спосіб лікування генералізованого пародонтиту
ATE249229T1 (de) Verwendung von putamen ovi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application